CAS: 774538-96-4; (Z)-7-Chloro-2-(3-(1-((Cyclopropylmethyl)Thio)-3-(2-Isopropylphenyl)Propyl)Styryl)Quinoline

该化合物是一种化学化合物,用作利心受体对立物,主要用于治疗哮喘和过敏鼻炎,抑制利心炎,抑制其作用,阻止其作用,因为它是煽动性调解器,有助于胸肠收缩和肌肉生产."cis"指分子的具体几何结构,可影响其生物活动以及与受体的互动.Cis-Montelukast一般是口服的,以其优美的药用基因特征著称,包括口服良好的生物利用率和长半衰期,允许一次性服用.该化合物一般使用良好,其副作用可能包括头痛,胃肠扰动和罕见的情绪变化.该特性在减少哮喘症状和改善肺功能方面的功效使其在呼吸医学中成为宝贵的治疗选择.与任何药物一样,病人咨询保健专业人员进行个人化咨询和管理十分重要.

结构式图片

MSDS等安全信息

    上下游产品

    Montelukast sodium

    合成工艺路线路线简述

      📜Montelukast Sodium 反应生成 孟鲁司特杂质g
      参考文献:10.1002/chir.23610
      标题:10.1002/chir.23610
      摘要:Abstractmontelukast Sodium (Mls) Is A Leukotriene Receptor Antagonist That Relieves Asthma,Bronchospasm,Allergic Rhinitis,And Urticaria. A Simple,Robust,And Stability‐indicating Normal Phase High‐performance Liquid Chromatography Method Was Developed To Separate And Quantitatively Estimate The S‐enantiomer Of Mls. The Chiral Separation Was Achieved Using Usp L51 Packing Material Along With A Mobile Phase Consisting Of A Solvent Mixture (N‐hexane,Ethanol,And Propionic Acid),A Flow Rate Of 1.0 Ml/min,A Detection Wavelength Of 284 Nm,A Column Temperature Of 30oc And An Injection Volume Of 20 μl. The Enantiomers Peaks Were Well Separated From The Peaks Of The Placebo,Diluting Solvent,Mls,And Its Known Impurities With A Resolution Of More Than 2.2 And With No Interference. Accuracy And Linearity Were Studied In A Range Of 0.36-3.597 μg/ml (0.03%-0.30%),With Good Recoveries Between 92.5% And 96.8% And A Linear Regression Coefficient Above 0.996. The Suggested Chiral Chromatography Method Is Being Considered As An Alternative And Equivalent Method To The United States Pharmacopeia And European Pharmacopeia Monographs. The Developed Method Was Effectively Employed For The Study Of Release And Stability Samples Of Mls. This HPLC Method Is Also Capable Of Separating And Estimating The Stereo‐selective Isomers (R‐ And S‐enantiomers) Of Sulfoxide Impurity Of Mls In Pharmaceutical Medicine.
      DOI:10.1002/chir.23610

      海关参考信息

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知